Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Heidt

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2023
Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in ChondrosarcomaVivek Subbiah, Sant P Chawla, Anthony P Conley, et al.
Cancer Research|August 10, 2013
An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulinAndrew P Garner, Carl U Bialucha, Elizabeth R Sprague, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2023
Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in ChondrosarcomaVivek Subbiah, Sant P Chawla, Anthony P Conley, et al.
Cancer Research|August 10, 2013
An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulinAndrew P Garner, Carl U Bialucha, Elizabeth R Sprague, et al.
Pageof 2